Notícias

Moderna stock rallies as Wolfe Research upgrades it to "Peer Perform." But is there any further upside left in MRNA shares? Let’s find out!

Merck stock sits near analyst targets that fall short of $200, yet a compressed fall calendar of FDA decisions and a pivotal cancer vaccine readout could force Wall Street to rethink the entire post-KEYTRUDA story.

Moderna and Merck’s personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.

Three catalysts, one reshuffling, and a Fed that refuses to move

Moderna Stock Jumps as Wolfe Upgrade Puts Cancer Pipeline in Spotlight

The S&P 500 Index ($SPX ) (SPY ) is up by +0.16% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.51%. E-mini S&P futures (ESU26 ) are up +0.15%, and September E-mini...

Moderna and Merck’s personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.

Moderna just posted an 11% surge with zero news behind it, while its longtime mRNA peer BioNTech can barely keep pace with the broader biotech sector. Something broke between these two names, and figuring out what it means for your position is more urgent than it looks.

Jim Cramer declared the data center trade dead on live television and named the stocks he wants instead, but the rotation he described carries a flaw that Wall Street is quietly ignoring.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5%, and the actively tra

Wall Street is making bold moves Tuesday, upgrading AMD and shaking up fintech names like Klarna and Shift4 while fresh initiations hit Fortune Brands and Jersey Mike's. Find out which stocks analysts are backing and which they are walking away from.

Stock futures were rising early Tuesday as the tech sector, and chip stocks in particular, looked set to rebound.

Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not all of them carry the same risk.

Moderna (NASDAQ:MRNA) shares rose 2. 9% in pre-market trading, recovering some ground after several sessions of declines that followed a dramatic rally triggered by positive Phase 3 results for its personalised mRNA cancer vaccine, intismeran autogene.

A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure profits following the extraordinary run. The sector had jumped after Phase 3 results for Moderna’s individualized neoantigen mRNA therapy, intismeran, used with Merck’s Keytruda — the first positive late-stage readout for an mRNA-based cancer vaccine over Keytruda alone. With no fresh clinical or regulatory catalyst to extend the advance, the tape has shifted

Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.

The biotech fund is one of two ETFs in IBD Leaderboard. The S&P 500 Biotech index gapped up to nearly an all-time high last Wednesday, a bullish day for the industry. While Moderna shares have remained volatile since then — down 23.5% Thursday after rising 177% Wednesday — the biotech ETF is doing its job as a diversified fund, keeping its one-day price moves to within 6%.

While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.

MRNA's cancer therapy scores a phase III win, strengthening its mRNA platform, while pipeline risks and competition remain key concerns.

Moderna just handed back 7% of its staggering year-to-date run in a single session, and the question rattling traders is whether this is a routine exhale or the beginning of a painful unwind for latecomers.

FEATURE Top executives at Moderna have been projecting high confidence in the commercial future of the company’s personalized cancer vaccine even as Wall Street holds out for complete trial results. The market reacted instantly to the initial readout.

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

Merck added billions in a single day after its Moderna-partnered cancer vaccine cleared a major hurdle.

Nvidia (NVDA) is just days away from releasing second quarter earnings results this Wednesday, August 26, as Wall Street expects quarterly revenue of $92 billion. The Morning Brief's Jake Conley sits down with Barron's senior markets analysis writer Paul La Monica and Infrastructure Capital Advisors CEO Jay Hatfield to discuss why excellent earnings may still not be enough to impress investors in this stage of the AI cycle.

Eyes are now on intismeran’s upcoming Phase II RCC readout, which they say could signal the drug’s wider potential across the solid tumour space.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Stock futures are falling to start the week with tech names leading the way lower ahead of Nvidia’s key earnings report.

A German report claimed Regal hit its 80th event, but Sellas has not confirmed it.

Tempus AI's latest acquisition is looking like a great move.

Moderna has always been a stock driven by narrative extremes. During the pandemic, it traded as if mRNA would transform medicine overnight, with its market capitalization peaking near $200 billion. Shares exploded 177% in a single session on Wednesday—the largest one-day surge for an S&P 500 company in over two decades—after Moderna and partner Merck reported successful late-stage trial results for their personalized mRNA melanoma vaccine.